Product Description
NBI-74330 is a small molecular high affinity CXCR3 antagonist that is a potent inhibitor of CXCR3 ligand binding with a Ki in the low nanomolar range (8 nmol/L). In vitro data have shown that it inhibits CXCL10 and ITAC induced calcium mobilization at concentrations below 10 nmol/L.
Mechanisms of Action: CXCR3 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
02/29/2024 |
PubMed |
Homocysteine modulates CXCL10/CXCR3 axis activity to induce endothelial dysfunction. |
|
07/30/2023 |
PubMed |
Targeting Members of the Chemokine Family as a Novel Approach to Treating Neuropathic Pain. |
|
05/01/2023 |
PubMed |
CXCR3 antagonist NBI-74330 mitigates joint inflammation in Collagen-Induced arthritis model in DBA/1J mice. |